- Home
- SXC vs EOLS Comparison
SXC vs EOLS Comparison
Compare SXC & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXC
- EOLS
- Stock Information
- Founded
- SXC 1960
- EOLS 2012
- Country
- SXC United States
- EOLS United States
- Employees
- SXC N/A
- EOLS N/A
- Industry
- SXC Steel/Iron Ore
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- SXC Industrials
- EOLS Health Care
- Exchange
- SXC Nasdaq
- EOLS Nasdaq
- Market Cap
- SXC 802.2M
- EOLS 702.2M
- IPO Year
- SXC N/A
- EOLS 2018
- Fundamental
- Price
- SXC $9.20
- EOLS $13.99
- Analyst Decision
- SXC Strong Buy
- EOLS Strong Buy
- Analyst Count
- SXC 1
- EOLS 6
- Target Price
- SXC $13.00
- EOLS $23.80
- AVG Volume (30 Days)
- SXC 1.1M
- EOLS 824.4K
- Earning Date
- SXC 01-30-2025
- EOLS 03-04-2025
- Dividend Yield
- SXC 5.22%
- EOLS N/A
- EPS Growth
- SXC 64.98
- EOLS N/A
- EPS
- SXC 1.12
- EOLS N/A
- Revenue
- SXC $1,935,400,000.00
- EOLS $248,326,000.00
- Revenue This Year
- SXC N/A
- EOLS $34.38
- Revenue Next Year
- SXC $3.70
- EOLS $31.94
- P/E Ratio
- SXC $8.21
- EOLS N/A
- Revenue Growth
- SXC N/A
- EOLS 34.42
- 52 Week Low
- SXC $7.47
- EOLS $9.25
- 52 Week High
- SXC $12.82
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- SXC 34.90
- EOLS 54.04
- Support Level
- SXC $9.74
- EOLS $14.50
- Resistance Level
- SXC $10.08
- EOLS $15.06
- Average True Range (ATR)
- SXC 0.30
- EOLS 0.86
- MACD
- SXC -0.00
- EOLS -0.00
- Stochastic Oscillator
- SXC 4.84
- EOLS 27.38
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.